The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges.

Target Oncol · 2021 · PMC8484171 · PMID 34554353

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

Moreover, long-term follow-up results from the EORTC 18991 trial revealed a diminished impact of adjuvant pegylated IFN-α 2b as compared with the benefit seen in the initial trial results and showed only a marginally significant impact on RFS, whereas no increase in OS or distant metastasis-free survival has been observed [ 27 ].

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.